Roxadustat for anemia in patients with kidney disease not receiving dialysis

New England Journal of Medicine

Volumn 381, Issue 11, 2019, Pages 1001-1010

  Chen, Nan ^a   Hao, Chuanming ^b   Peng, Xiaomei ^c   Lin, Hongli ^e   Yin, Aiping ^f   Hao, Li ^g   Tao, Ye ^h   Liang, Xinling ⁱ   Liu, Zhengrong ^j   Xing, Changying ^k   Chen, Jianghua ^m   Luo, Laimin ⁿ   Zuo, Li ^o   Liao, Yunhua ^d   Liu, Bi Cheng ^l   Leong, Robert ^p   Wang, Chunrong ^p   Liu, Cameron ^p   Neff, Thomas ^p   Szczech, Lynda ^p   Yu, Kin Hung P ^p   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^d GUANGXI MEDICAL UNIVERSITY   (China)

^e DALIAN MEDICAL UNIVERSITY   (China)

^f XI'AN JIAOTONG UNIVERSITY   (China)

^g ANHUI MEDICAL UNIVERSITY   (China)

^h SICHUAN UNIVERSITY   (China)

ⁱ GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^j SOUTHERN MEDICAL UNIVERSITY   (China)

^k NANJING MEDICAL UNIVERSITY   (China)

^l MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^m ZHEJIANG UNIVERSITY   (China)

ⁿ NANCHANG UNIVERSITY   (China)

^o PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^p FibroGen   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN; PLACEBO; ROXADUSTAT; ANTIANEMIC AGENT; FG-4592; GLYCINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; ISOQUINOLINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ACIDOSIS; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED;

ACIDOSIS; ADULT; AGED; ANEMIA; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; GLYCINE; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERKALEMIA; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; ISOQUINOLINES; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 85072133755     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1813599     Document Type: Article

References (36)

1. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012;379: 815-22.
2. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998;32:Suppl 4:S133-S141.
3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
4. United States Renal Data System. USRDS 2013 annual data report: 2013 atlas of CKD & ESRD. 2013 (https://www.usrds.org/atlas13.aspx).
5. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
6. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
7. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
8. Liu L, Yang L, Wang M. The clinical stage at which dialysis began in patients with non-diabetic end stage renal disease: a retrospective study. Chin J Blood Purif 2007:242-6.
9. Zhu LN, Lv W, Teng J, et al. Association of residual renal function at initiation of dialysis with prognosis in maintenance dialysis patients. Chin J Nephrol 2012:757-64.
10. Zhang W, Gong Z, Peng X, Tang S, Bi M, Huang W. Clinical characteristics and outcomes of rural patients with ESRD in Guangxi, China: one dialysis center experience. Int Urol Nephrol 2010;42:195-204.
11. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111:992-1000.
12. Muirhead N. A rationale for an individualized haemoglobin target. Nephrol Dial Transplant 2002;17:Suppl 6:2-7.
13. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-91.
14. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:Suppl 2:ii2-ii6.
15. Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol 2007;2:215-21.
16. Seliger S, Fox KM, Gandra SR, et al. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephrol 2010;5:882-8.
17. Levin A. The treatment of anemia in chronic kidney disease: understandings in 2006. Curr Opin Nephrol Hypertens 2007;16:267-71.
18. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-8.
19. Hörl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301.
20. Procrit: Highlights of prescribing information. Thousand Oaks, CA: Amgen, 2012 (package insert).
21. Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 2015;30:1665-73.
22. Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 2016;27:1225-33.
23. Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 2016; 11:982-91.
24. Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 2016;67:912-24.
25. Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant 2017;32:1373-86.
26. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823:1434-43.
27. Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 1997;272:20055-62.
28. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006;26:323-42.
29. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117:1926-32.
30. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85.
31. Nguyen AD, McDonald JG, Bruick RK, DeBose-Boyd RA. Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of insigs. J Biol Chem 2007;282:27436-46.
32. Hwang S, Nguyen AD, Jo Y, Engelking LJ, Brugarolas J, DeBose-Boyd RA. Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J Biol Chem 2017;292:9382-93.
33. Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. Am J Nephrol 2011;34:195-202.
34. Ku E, Campese V. Is lipid management effective for all stages of CKD? Blood Purif 2013;35:26-30.
35. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1-150 (https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012 _CKD_GL.pdf).
36. Chen N, Hao C, Liu B-C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 2019;381:1011-22.